Abstract: Objective To explore the tolerability，safety and efficacy of cetuximab combined with cisplatin chemotherapy and concurrent intensity-modulated radiation therapy（IMRT）for the first-treated locally advanced nasopharyngeal carcinoma. Methods Eight patients with histologically proved locally advanced nasopharyngeal carcinoma admitted from August 2008 to April 2009 were treated with cetuximab combined with cisplatin chemotherapy and IMRT. Cisplatin（80mg／m2 once every 3 weeks for 2 weeks） and cetuximad（400mg／m2 once a week before radiation， and then 250mg／m2 per week with a total of 7-8 times）were given concurrently. The planned doses of IMRT in target region were 69.96-73.92Gy in 33 fractions. The tolerability，safety and efficacy were followed up. Results All patients have completed the treatment as planned. All following-up interval was 36 months with survival. Acute side reaction included：8 patients all had grade1or 2 skin rash reaction，2 cases of grade 3 bone marrow suppression，2 cases of grade 3 oral mucositis. No toxicity of grade 4 occurred. All patients were re-examined when three months after therapy with CR in 5 patients and PR in 3 cases. Two cases had nasopharyngeal local recurrence. Both the two patients received reprocess treatment with 1 case CR and 1 up to PR. The remaining patients were followed up for no disease progression-free survival. Conclusion The treatment of cetuximab combined with cisplatin chemotherapy and IMRT with locally advanced nasopharyngeal carcinoma has shown better safety，tolerability and clinical outcome. However，the long-term efficacy needs to expand cases and further followup observation.